PEXA AB |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.373 SEK | +8.12% |
|
+3.61% | -9.90% |
| 02-21 | PExA AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
| 02-21 | PExA AB Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2021 | 2.16M 197K 15.73M | Sales 2022 | 6.03M 550K 43.87M | Capitalization | 27.23M 2.49M 198M |
|---|---|---|---|---|---|
| Net income 2021 | -7M -639K -50.94M | Net income 2022 | -4M -365K -29.11M | EV / Sales 2021 | 13.5 x |
| Net cash position 2021 | 20.72M 1.89M 151M | Net cash position 2022 | 18.25M 1.67M 133M | EV / Sales 2022 | 1.49 x |
| P/E ratio 2021 |
-4.95
x | P/E ratio 2022 |
-5.73
x | Employees | 3 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 0% |
More Fundamentals
* Assessed data
More news
| 1 day | +8.12% | ||
| 1 week | +3.61% | ||
| Current month | -15.23% | ||
| 1 month | -15.23% | ||
| 3 months | -17.11% | ||
| 6 months | -25.40% | ||
| Current year | -9.90% |
1 week
0.35
0.38
1 month
0.350.44
Current year
0.330.58
1 year
0.331.06
3 years
0.332.56
5 years
0.334.24
10 years
0.3315.50
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 53 | - | |
Jörgen Östling
CTO | Chief Tech/Sci/R&D Officer | - | - |
Svante Höjer
CTO | Chief Tech/Sci/R&D Officer | 63 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 68 | 31/12/17 | |
| Director/Board Member | 71 | 31/12/20 | |
| Chairman | 70 | 31/12/11 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/04/24 | 0.373 | +8.12% | 42,564 |
| 26/04/24 | 0.345 | -1.71% | 1,100 |
| 25/04/24 | 0.351 | -9.77% | 3,043 |
| 23/04/24 | 0.389 | +8.06% | 2,943 |
End-of-day quote NORDIC GROWTH MARKET, April 28, 2024
More quotes
PExA AB is a Sweden-based company engaged in the advanced equipment and technology industry. The Company develops, manufactures and markets a non-invasive research instrument to study respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD). The instrument provides lung researchers with a non-invasive method for collecting microscopic particles, potential biomarkers for diseases, from small airways in exhaled air to diagnose, monitor and provide treatment of respiratory diseases.
Calendar
19/08/2024
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -9.90% | 1.33M | |
| -12.42% | 19.08B | |
| -46.59% | 2.65B | |
| +17.50% | 1.87B | |
| -0.58% | 1.61B | |
| +25.36% | 1.21B | |
| -8.67% | 1.02B | |
| -21.91% | 905M | |
| -4.42% | 716M | |
| -17.51% | 682M |
- Stock Market
- Equities
- PEXA B Stock
